ARCS reaches a new horizon with LifeSciences Australia rebrand

ARCS has announced its transition to a new identity, becoming LifeSciences Australia, unveiled at its annual conference. The change reflects the organisation’s expanding professional community and its broader role in supporting Australia’s life sciences ecosystem.

The clinical trials sector contributes an estimated $250 billion to the national economy and supports close to 350,000 jobs. LifeSciences Australia now represents more than 38,000 professionals across 3,300 organisations, spanning early-stage research and clinical development through to regulatory advancement and commercialisation.

Dr Tim Boyle, CEO of LifeSciences Australia, said “For more than 40 years, ARCS has supported the professionals advancing healthcare innovation across Australia. Over that time, both the sector and the professions within it have developed significantly, and the organisation has grown alongside them.”

“This evolution is about recognition rather than reinvention. LifeSciences Australia better reflects who we are today, providing our members and the broader community with greater clarity around our role and strengthening our ability to support the future growth, capability and leadership of Australia’s life sciences secto,” added Dr Boyle.

The rebrand follows extensive consultation with members and stakeholders throughout 2025, which identified a growing need for an identity that more accurately represents the organisation’s expanding remit and reinforces the professional standing of its members.

Professor John Skerritt AM, Enterprise Professor in Health Research Impact at the University of Melbourne, member of the Boards of Medicines Australia and AusBiotech, and former senior government official, said the sector’s continued growth highlighted the importance of recognising the expertise and contribution of the professionals who underpin the life sciences capability.

“As the sector continues to expand, clearer recognition of the professions and expertise of individuals underpinning Australia’s life sciences capability becomes increasingly important,” he said. “A strong professional association helps support constructive engagement. LifeSciences Australia provides a more unified and recognisable identity for the professionals working across Australia’s life sciences sector, helping strengthen professional networks, capability and connections into the future.”

LifeSciences Australia will bring together the organisation’s expanding programs and initiatives under an ecosystem of sub-brands ARCS, Cognitio, BioBeacon and Horizons, creating a clearer structure to support professionals throughout their careers. A 12-month review of these sub-brands will identify opportunities for future consolidation or expansion.

Shan-Shan Wang, Founder & CEO, Roam Technologies, said “I’ve learned first-hand that building a life sciences company in Australia requires more than great science and technology. Success depends on access to mentors, networks, industry expertise and opportunities to learn from others who have navigated the same journey.

“BioBeacon is so important because it bridges the gap between research, innovation and commercialisation, helping emerging innovators and entrepreneurs turn promising ideas into real-world impact. Under the LifeSciences Australia umbrella, I’m excited to see initiatives like this continue to grow, strengthening Australia’s pipeline of future life sciences companies and the industry as a whole.”

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.